Abiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts
March 30 2017 - 12:27PM
Massachusetts Governor Charlie Baker today joined Abiomed – a
leading provider of breakthrough heart support and recovery
technologies – for the grand opening of its newly expanded global
headquarters in Danvers.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/a85c5b1d-6799-4fc6-b6bb-40e104632b3a.
With the expansion, Abiomed more than doubles the
size of its headquarters from 60,000 square feet to 160,000 square
feet adding new research and manufacturing capabilities, along with
the new Heart Recovery Institute for clinical education – a cutting
edge training facility. It represents a more than $40 million
investment in Massachusetts for education, manufacturing, and
training.
“With Massachusetts-based companies like Abiomed
helping to lead the way, the Commonwealth continues to be a global
leader in health care, innovation and technology,” said Governor
Charlie Baker. “I am pleased to continue to witness the growth of a
company that has invested in Massachusetts for more than 35 years
and we look forward to continuing to work together to create jobs
and develop the state’s innovation economy.”
Abiomed broke ground on the construction in June
2015 and has since added more than 150 engineering and
manufacturing jobs to the site. The company now has more than 400
employees in Massachusetts, over 700 in the United States, and
globally is nearing 1,000. Abiomed is also expanding its capacity
in Berlin and Aachen, Germany and Tokyo, Japan.
“Today we recognize 35 years of dedication and hard
work by all the people who made this possible – from employees, to
customers, to patients, to investors,” said Abiomed President,
Chairman and CEO Mike Minogue. “We celebrate our Patients First
culture and this investment in our future. We are proud to add new
clinical, engineering and manufacturing jobs in Massachusetts
because it will ensure faster innovation, quality, and compliance.
Our mission is to help recover hearts; now we have the
manufacturing infrastructure to support enough patients to fill
Fenway Park each year.”
During the event, Abiomed also recognized two
cardiac patients that benefited from the company’s lifesaving
technology. Conference rooms were named in honor of milestone
patients Rogelio Landin of Detroit, MI and Howard Gaynor of
Hartford, CT. Robert Pasquariella, a patient treated with the
Impella device from Everett, Mass., also attended the event with
his son Bobby who was part of the construction team that worked on
the expansion.
Abiomed has been in Massachusetts since 1981,
securing three FDA approvals and earning 264 patents with another
237 pending. The company recently announced that it has supported
more than 50,000 patients in the U.S. with Impella®, the world’s
smallest heart pump – which can help the heart rest, recover and in
some cases, heal.
Abiomed is the only company with FDA approval for
heart recovery and the Impella is the only FDA-approved
percutaneous hemodynamic support device approved safe and effective
for the treatment of high risk patients, and patients with Acute
Myocardial Infarction Cardiogenic Shock (AMICS).
ABOUT IMPELLA HEART PUMPS
The Impella 2.5®, Impella CP® and Impella 5.0® are
FDA-approved heart pumps used to treat heart attack patients in
cardiogenic shock, and have the unique ability to enable native
heart recovery, allowing patients to return home with their own
heart. The Impella 2.5 and Impella CP devices are also approved to
treat certain advanced heart failure patients undergoing elective
and urgent percutaneous coronary interventions (PCI) such as
stenting or balloon angioplasty, to re-open blocked coronary
arteries. Abiomed's right-side heart pump, the Impella RP® device,
is approved to treat certain patients experiencing right heart
failure. To learn more about the Impella platform of heart pumps,
including their approved indications and important safety and risk
information associated with the use of the devices, please visit:
www.protectedpci.com.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements,
including statements regarding development of Abiomed's existing
and new products, the Company's progress toward commercial growth,
and future opportunities and expected regulatory approvals. The
Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number
of factors, including uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
Media Contact
Laura Wareck
lwareck@oneillandassoc.com | 978-660-9587
Adrienne Smith
adsmith@abiomed.com |781-277-1170
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024